G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/68 (2006.01) C07K 14/47 (2006.01) C07K 14/74 (2006.01) C07K 14/805 (2006.01) C07K 14/81 (2006.01) G01N 33/53 (2006.01)
Patent
CA 2496321
A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific markers in body fluids (e.g. CSF), using mass spectrometric analysis (SELDI-TOF MS). The specific markers are: human cystatin C, human beta-2-microglobulin, human myoglobin neurosecretory protein VGF or fragments of these proteins.
La présente invention concerne un procédé permettant de vérifier l'état de la maladie d'Alzheimer chez des patients. L'invention concerne également un procédé permettant de suivre la progression de la maladie d'Alzheimer chez des patients. Le procédé met en oeuvre la détection de marqueurs peptides spécifiques, notamment grâce à l'analyse par spectrométrie de masse.
Carrette Odile
Hochstrasser Denis Francois
Koenig Gerhard
Sanchez Jean-Charles
Yalkinoglu Oezkan
Bayer Healthcare Ag
Bayer Schering Pharma Aktiengesellschaft
Fetherstonhaugh & Co.
LandOfFree
Biomarkers for diagnosing alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for diagnosing alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for diagnosing alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1638312